

## Market Round-up

V38 – 12<sup>th</sup> July, 2019

### Drug Approvals/Filings:

- The Scottish Medicines Consortium (SMC) has recommended **Janssen's Darzalex®** (daratumumab) plus bortezomib and dexamethasone as an option for treating **relapsed multiple myeloma**.  
[LINK](#)
- **Bayer** is to apply to the **European Medicines Agency** for approval to make its blockbuster blood thinner **Xarelto** available for treating children.  
[LINK](#)
- The **FDA** is to review **Sanofi's isatuximab** as a potential treatment for relapsed/refractory **multiple myeloma**.  
[LINK](#)
- **AstraZeneca's** cancer drug **Imfinzi** granted U.S. orphan status  
[LINK](#)

### Biosimilars/Biologics:

- In treating **RA pain**, could **JAK Agents** beat **Adalimumab**?  
[LINK](#)
- **Prestige BioPharma** and **Mundipharma** have signed an agreement giving the **trastuzumab** biosimilar access across a number of European countries following the drug's approval by the European Commission.
- The **FDA** is to review **Sanofi's isatuximab** as a potential treatment for relapsed/refractory **multiple myeloma**.  
[LINK](#)
- **UK Hospital** - The Luton and Dunstable University Hospital - reports slightly uneven results of **Rituximab** switch.  
[LINK](#)
- In a win for **Amgen**, Court blocks **Sanofi/Regeneron's Praluent** sales in Germany  
[LINK](#)
- Positive framing from HCP's improves patients' willingness to switch to biosimilar  
[LINK](#)

### Mergers & Acquisitions:

- The EC approves **GSK's** acquisition of **Pfizer's** Consumer Health Business, subject to conditions  
[LINK](#)

### NCPE Drug Updates

- The NCPE recommends that **Novartis's ribociclib** not be considered for reimbursement at the submitted price. A full HTA is not recommended.

## General Market News:

- **Takeda Ireland** have opened a state-of-the-art cancer drug manufacturing plant in Dublin.  
[LINK](#)
- **AstraZeneca** has announced plans to appeal **NICE's** decision to reject its non-small cell lung cancer (NSCLC) drug, *Tagrisso*.  
[LINK](#)
- **Celsius Therapeutics** and **Janssen** sign collaboration agreement into an **IBD** study.  
[LINK](#)
- **Heat-stable carbetocin** – which was developed by **Ferring Pharmaceuticals** - has been added to the **WHO** Essential Medicines List of uterotonics for the prevention of excessive bleeding after childbirth.  
[LINK](#)
- Targeting toxic protein aggregation, German biotech **MODAG** is investing €12M to develop a drug for multiple system atrophy (**MSA**).  
[LINK](#)
- **Roche** have announced new data for **Hemlibra®** (emicizumab) across multiple pivotal studies in people with **haemophilia A**  
[LINK](#)
- No-deal **Brexit** will see checks on UK imports but not at border, says Government  
[LINK](#)
- **Amgen** and **Novartis** drop **Alzheimer's**-prevention study after patients worsened  
[LINK](#)

## Further Reading:

- **MSD** is among the consortium testing the potential to deliver temperature-controlled medicines and vaccines using a drone  
[LINK](#)
- Gaps in **dementia research** identified by leading dementia experts  
[LINK](#)
- Pressing the pause button on CAR-T cells with **Bristol-Myers' leukemia** drug **Sprycel**  
[LINK](#)
- **Galway University Hospital** has introduced robotic **prostate** surgery  
[LINK](#)
- **The NHS** plans to collaborate with **Amazon** to provide “reliable health information from the NHS website through Alexa.”  
[LINK](#)